No connection

Search Results

FORA vs GOSS

FORA
Forian Inc.
BEARISH
Price
$2.14
Market Cap
$66.9M
Sector
Healthcare
AI Confidence
80%
GOSS
Gossamer Bio, Inc.
BEARISH
Price
$0.37
Market Cap
$87.2M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
FORA
--
GOSS
--
Forward P/E
FORA
23.78
GOSS
-2.23
P/B Ratio
FORA
2.23
GOSS
-0.71
P/S Ratio
FORA
2.21
GOSS
1.8
EV/EBITDA
FORA
-9.93
GOSS
-0.94

Profitability

Gross Margin
FORA
53.21%
GOSS
100.0%
Operating Margin
FORA
-24.44%
GOSS
-333.65%
Profit Margin
FORA
-9.5%
GOSS
0.0%
ROE
FORA
-9.61%
GOSS
--
ROA
FORA
-5.15%
GOSS
-41.86%

Growth

Revenue Growth
FORA
37.0%
GOSS
47.1%
Earnings Growth
FORA
--
GOSS
--

Financial Health

Debt/Equity
FORA
0.0
GOSS
--
Current Ratio
FORA
2.96
GOSS
2.64
Quick Ratio
FORA
2.78
GOSS
2.36

Dividends

Dividend Yield
FORA
--
GOSS
--
Payout Ratio
FORA
0.0%
GOSS
0.0%

AI Verdict

FORA BEARISH

FORA exhibits severe fundamental weakness as evidenced by a Piotroski F-Score of 2/9, indicating poor operational efficiency and financial health. While the company maintains a debt-free balance sheet and strong liquidity (Current Ratio 2.96), it is struggling to translate 37% revenue growth into bottom-line profitability. The technical trend is completely bearish (0/100) and the 5-year price performance is devastating (-82.8%), suggesting a long-term loss of investor confidence. Despite a healthy gross margin of 53.21%, the negative operating margins and lack of deterministic value markers make this a high-risk speculative play.

Strengths
Zero debt (Debt/Equity: 0.00)
Strong short-term liquidity (Current Ratio: 2.96)
Robust revenue growth (37% YoY)
Risks
Critically low Piotroski F-Score (2/9) indicating fundamental deterioration
Negative operating margins (-24.44%)
Severe long-term price depreciation (-82.8% over 5 years)
GOSS BEARISH

GOSS exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating the weakest possible fundamental health. The company suffers from negative equity (Price/Book of -0.71) and an unsustainable operating margin of -333.65%. Despite positive revenue growth, the stock is in a catastrophic technical death spiral, losing over 85% of its value in the last six months. The massive discrepancy between the current price ($0.37) and the analyst target ($3.69) suggests a significant lag in analyst updates or extreme speculative optimism not supported by the deterministic data.

Strengths
Strong YoY revenue growth of 47.10%
Healthy short-term liquidity with a Current Ratio of 2.64
Quick Ratio of 2.36 suggests immediate obligations can be met
Risks
Negative Book Value (P/B -0.71) indicating liabilities exceed assets
Piotroski F-Score of 0/9 signals severe fundamental deterioration
Extreme price decay with a 5-year decline of 95.6%

Compare Another Pair

FORA vs GOSS: Head-to-Head Comparison

This page compares Forian Inc. (FORA) and Gossamer Bio, Inc. (GOSS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile